Lung Cancer
Conference Coverage
Neoantigen vaccine appears safe and active in NSCLC
NATIONAL HARBOR, MD. – The vaccine produced only grade 1 adverse events and yielded responses in 7 of 24 patients,...
News
Lorlatinib induces deep responses in ROS1-positive NSCLC
Among 40 crizotinib-pretreated patients, 14 patients (35%) had an objective response on lorlatinib, with a median duration of response of 13.8...
Latest News
Levothyroxine dose for checkpoint inhibitor toxicity may be too high
CHICAGO – Dosing need not be automatically boosted when starting checkpoint inhibitor therapy.
Conference Coverage
Immune checkpoint inhibition in SCLC: Modest outcomes, many questions
Immune checkpoint inhibitors have activity in SCLC, but achieving more durable disease control and better survival requires greater understanding...
Conference Coverage
Osimertinib improves survival in advanced NSCLC
BARCELONA – Osimertinib is the first TKI to show a survival advantage over another in advanced non–small cell lung cancer, FLAURA investigators...
Article
Lung Cancer in the VA at a National Level
News
Many institutions exceed recommended radiation doses during lung cancer screening
Allowing any radiologist, rather than a lead radiologist, to establish CT protocols is associated with high likelihood of exceeding ACR dose...
News
Prior antibiotic use lowers checkpoint inhibitor response and survival
Patients who take antibiotics in the 30 days prior to starting checkpoint inhibitor therapy for cancer have significantly lower overall survival...